Plaintiffs in the MDL allege that manufacturers, including Novo Nordisk and Eli Lilly, failed to provide timely and adequate warnings about gallbladder risks despite emerging clinical data and post-market adverse event reports
Neither has published long-term hard-outcome data such as cardiovascular events or mortality, which is the kind of evidence that ultimately defines a metabolic drugs value
enhanced their endogenous level of antioxidant content and efficacy of glyoxalase systems to boost their antioxidant capacity under different unfavorable stressful environments 12,13,14,15
Kidney injury appears only as a secondary effect of dehydration from severe gut upset. Anti-drug antibodies form in roughly half to two-thirds of users but do not affect clearance, weight, or blood sugar. Benefits that look like side effects Tirzepatide lowers uric acid (about -0.7 to -1.0 mg/dL, mostly through weight loss) and lowers blood pressure
The American Gastroenterological Association (AGA) released a clinical practice update and found insufficient data to support patients stopping GLP-1 medication prior to elective endoscopy procedures